- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- Rilvegostomig, Pembrolizumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 39
- States / cities
- La Mesa, California • Los Alamitos, California • Newark, Delaware + 36 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 618
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Participants
- Interventions
- Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Hollywood, Florida
- Conditions
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Indolent Non-Hodgkin Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib, Pegfilgrastim, Polatuzumab Vedotin, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Follicular Lymphoma
- Interventions
- DRL_RI (Proposed rituximab biosimilar), MabThera®
- Biological · Other
- Lead sponsor
- Dr. Reddy's Laboratories Limited, India
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Whittier, California • Bethesda, Maryland • Knoxville, Tennessee + 1 more
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, Glioma, Oligoastrocytoma, Oligodendroglioma, WHO Grade 3 Glioma
- Interventions
- Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
- Procedure · Radiation · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2031
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Boca Raton, Florida • Miami, Florida + 27 more
- Conditions
- Adenomatous Polyposis Coli
- Interventions
- Erlotinib, Sulindac, Placebo A, Placebo B
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Hypogonadism
- Interventions
- dutasteride, placebo
- Drug
- Lead sponsor
- The Miriam Hospital
- Other
- Eligibility
- 40 Years to 85 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Providence, Rhode Island
- Conditions
- Healthy
- Interventions
- Gabapentin 400 mg capsules, NEURONTIN® 400 mg capsules, Gabapentin 400 mg capsules, single dose
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 1998
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Oral Nutrition Supplement
- Other
- Lead sponsor
- Société des Produits Nestlé (SPN)
- Industry
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Tustin, California
- Conditions
- Invasive Aspergillosis, Invasive Pulmonary Aspergillosis
- Interventions
- Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
- Drug
- Lead sponsor
- Vical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • La Jolla, California • Sacramento, California + 8 more
- Conditions
- Opioid Users
- Interventions
- Capsule, PF-00345439, oxycodone
- Drug
- Lead sponsor
- Pain Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Ureteral Injury
- Interventions
- Pyridium, Riboflavin, Thiamine
- Drug
- Lead sponsor
- Texas Tech University Health Sciences Center
- Other
- Eligibility
- 21 Years to 75 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Lubbock, Texas
- Conditions
- Smoking Behaviors
- Interventions
- Modified Risk - None, Modified Risk Claim
- Behavioral
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Tooth Sensitivity
- Interventions
- Prof applied oxalate, Self applied oxalate, Prof applied placebo
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Healthy
- Interventions
- Propranolol Hydrochloride Extended Release Capsules 160 mg, INDERAL® LA 160 mg Capsules, single dose
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Healthy
- Interventions
- Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose, COMBONOX® tablets, single dose
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Gastrointestinal Dysfunction
- Interventions
- PreforPro+B. subtilis DE111 probiotics, Placebo, B. subtilis DE111
- Dietary Supplement
- Lead sponsor
- Colorado State University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Multiple Myeloma
- Interventions
- Talquetamab, Prophylaxis A, Prophylaxis B, Prophylaxis C, Prophylaxis D, Ramantamig
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 9
- States / cities
- San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more
- Conditions
- Advanced BRAF-mutant Cancers
- Interventions
- PX-866, vemurafenib
- Drug
- Lead sponsor
- Cascadian Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 5
- States / cities
- Tampa, Florida • New York, New York • Philadelphia, Pennsylvania + 2 more
- Conditions
- Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
- Interventions
- ABT-335 and rosuvastatin calcium, ABT-335 and atorvastatin calcium, ABT-335 and simvastatin
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,911 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- North Chicago, Illinois
- Conditions
- Diabetic Nephropathy
- Interventions
- CTP-499
- Drug
- Lead sponsor
- Concert Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Colorectal Neoplasms
- Interventions
- Nivolumab-relatlimab FDC, Regorafenib, TAS-102
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 20
- States / cities
- Springdale, Arkansas • Los Angeles, California • Norwich, Connecticut + 17 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia
- Interventions
- Azacitidine, Cytarabine, Decitabine, Laboratory Biomarker Analysis, Midostaurin, Nivolumab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 60 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 506
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 337 more
- Conditions
- Hand Hygiene
- Interventions
- Post-market foam alcohol-based hand sanitizer #1, Post-market foam alcohol-based hand sanitizer #2
- Drug
- Lead sponsor
- Medline Industries
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Evanston, Illinois